EBIT: Income before interest and taxes.
Iovance Biotherapeutics, Inc. (IOVA) had EBIT of $-51.91M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$99.31M |
|
$-47.31M |
|
$43.59M |
|
$55.72M |
|
$151.22M |
|
$-51.91M |
|
$3.22M |
|
$-48.69M |
|
$-48.69M |
|
$-47.31M |
|
$-47.31M |
|
$-47.31M |
|
$-47.31M |
|
|
EBIT |
$-51.91M |
$-44.04M |
|
450.19M |
|
450.19M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$464.26M |
|
$131.46M |
|
$451.27M |
|
$915.53M |
|
$106.85M |
|
-- |
|
$72.64M |
|
$179.49M |
|
$736.04M |
|
$472.15M |
|
$736.04M |
|
452.97M |
|
| Cash Flow Statement Financials | |
$-132.91M |
|
$-62.66M |
|
$143.62M |
|
$169.06M |
|
$116.77M |
|
$-52.28M |
|
$23.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
56.10% |
|
-52.26% |
|
-52.26% |
|
-- |
|
-49.02% |
|
-47.64% |
|
$-144.96M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.78 |
|
0.97 |
|
92.54 |
|
-6.43% |
|
-10.02% |
|
-5.17% |
|
-6.43% |
|
$1.62 |
|
$-0.32 |
|
$-0.30 |
|